What is InspireMD?
InspireMD, Inc. is a medical device firm dedicated to the advancement and market introduction of its unique MicroNet stent platform technology. This innovative technology is designed for the treatment of vascular and coronary diseases, with the company aiming to establish its products as the industry standard for carotid stenting. InspireMD's objective is to deliver superior acute results and sustained stroke-free outcomes over the long term. The company's common stock is publicly traded on the NYSE American under the ticker symbol NSPR, with certain warrants also available on the NYSE American under the symbols NSPR.WS and NSPR.WSB. Headquartered in Tel Aviv, Israel, InspireMD operates within the competitive landscape of cardiovascular medical devices.
How much funding has InspireMD raised?
InspireMD has raised a total of $109.1M across 3 funding rounds:
Debt
$11M
Private Equity
$40.1M
Stock/Share Issuance
$58M
Debt (2012): $11M, investors not publicly disclosed
Private Equity (2025): $40.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $58M supported by OrbiMed
Key Investors in InspireMD
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm deeply entrenched in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm's investment approach is characterized by a comprehensive understanding of healthcare innovation cycles and market dynamics, supporting companies from early-stage ventures to established organizations scaling proven solutions.
What's next for InspireMD?
The recent major strategic investment signals a pivotal moment for InspireMD, likely enabling the company to accelerate its product development pipeline, expand its market reach, and bolster its commercialization efforts. This influx of capital is expected to fuel further innovation in its MicroNet stent technology, potentially leading to expanded clinical applications and broader adoption within the healthcare sector. The company's public trading status on the NYSE American provides a platform for continued financial engagement and strategic partnerships as it navigates its growth trajectory.
See full InspireMD company page
